Debiopharm Innovation Fund, the Swiss biopharma’s strategic investing arm managing a $150 million fund, is looking to get involved earlier in the investment process with the launch of a new
A court in Germany has suspended a trial discussing litigation brought against BioNTech and Pfizer by CureVac alleging patent infringement in connection with their mRNA-ba
Digital health and wellness company Virgin Pulse has said it plans to merge with HealthComp, a health benefits administrator, in a $3 billion transaction that would create
The US government has set aside a $104 million pot of funding for research into bacterial behaviour and antibiotic resistance, in the hope of speeding up diagnosis and ena
In today’s complex communications landscape, the path of information from sender to recipient is not as straightforward as it once was.
Views & Analysis
White Papers & Webinar
Podcasts & Video
CRISPR-based therapies are undergoing a remarkable evolution, with drug developers striving to enhance the safety, precision and efficacy of their products.
CRISPR represents the next frontier in the cell and gene therapy landscape.
Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development.
Molecular glue development continues to gain exponential momentum, with advances in screening tools, identification assays and structure-based design.
The mRNA Assay Development Summit is the first and only meeting to address the specific technical challenges of analytical, bioanalytical and potency assay development.